Immunocytochemical analysis of the cervical Pap smear

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Although immunostained cervical Pap smears are not yet FDA approved for clinical use, it is very likely that they will become widely employed in the near future to identify neoplastic squamous and iendocervical glandular cells when screening liquid-based cytological preparations (i.e., SurePath or ThinPrep). The current problem with cytology complemented by high-risk human papillomavirus (HPV) testing is poor specificity. HPV testing provides superior sensitivity, but many women are infected with the virus, while very few have had persistent infections leading to carcinoma. Pathologists routinely use antibodies directed against the cyclin-dependent kinase inhibitor p16 (p16 INK4a) or a combination of antibodies directed against topoisomerase-2-alpha and minichromosome maintenance protein-2 (as in ProEx C) to improve diagnostic precision and accuracy in cervical tissue biopsies. This chapter will describe the immunocytochemical methods used by our group to immunostain cervical Pap smears and provide significantly improved positive predictive value when screening for cervical cancer.

Original languageEnglish (US)
Title of host publicationCervical Cancer: Methods and Protocols
PublisherSpringer New York
Pages203-212
Number of pages10
ISBN (Print)9781493920136, 9781493920129
DOIs
StatePublished - Oct 27 2014

Fingerprint

Papanicolaou Test
Vaginal Smears
Minichromosome Maintenance Proteins
Cyclin-Dependent Kinase Inhibitor p16
Antibodies
Uterine Cervical Neoplasms
Cell Biology
Viruses
Carcinoma
Biopsy
Infection
Pathologists

Keywords

  • CIN1
  • CIN2+
  • HSIL
  • Immunocytochemistry
  • Ki-67
  • Liquid-based cytology
  • LSIL
  • MCM-2
  • p16
  • Pap smear
  • Proexc
  • Topo-2a

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Morgan, T., & Berlin, M. (2014). Immunocytochemical analysis of the cervical Pap smear. In Cervical Cancer: Methods and Protocols (pp. 203-212). Springer New York. https://doi.org/10.1007/978-1-4939-2013-6_15

Immunocytochemical analysis of the cervical Pap smear. / Morgan, Terry; Berlin, Michelle.

Cervical Cancer: Methods and Protocols. Springer New York, 2014. p. 203-212.

Research output: Chapter in Book/Report/Conference proceedingChapter

Morgan, T & Berlin, M 2014, Immunocytochemical analysis of the cervical Pap smear. in Cervical Cancer: Methods and Protocols. Springer New York, pp. 203-212. https://doi.org/10.1007/978-1-4939-2013-6_15
Morgan T, Berlin M. Immunocytochemical analysis of the cervical Pap smear. In Cervical Cancer: Methods and Protocols. Springer New York. 2014. p. 203-212 https://doi.org/10.1007/978-1-4939-2013-6_15
Morgan, Terry ; Berlin, Michelle. / Immunocytochemical analysis of the cervical Pap smear. Cervical Cancer: Methods and Protocols. Springer New York, 2014. pp. 203-212
@inbook{b23d392d37bd4d75be29cefd4b4d5260,
title = "Immunocytochemical analysis of the cervical Pap smear",
abstract = "Although immunostained cervical Pap smears are not yet FDA approved for clinical use, it is very likely that they will become widely employed in the near future to identify neoplastic squamous and iendocervical glandular cells when screening liquid-based cytological preparations (i.e., SurePath™ or ThinPrep™). The current problem with cytology complemented by high-risk human papillomavirus (HPV) testing is poor specificity. HPV testing provides superior sensitivity, but many women are infected with the virus, while very few have had persistent infections leading to carcinoma. Pathologists routinely use antibodies directed against the cyclin-dependent kinase inhibitor p16 (p16 INK4a) or a combination of antibodies directed against topoisomerase-2-alpha and minichromosome maintenance protein-2 (as in ProEx™ C) to improve diagnostic precision and accuracy in cervical tissue biopsies. This chapter will describe the immunocytochemical methods used by our group to immunostain cervical Pap smears and provide significantly improved positive predictive value when screening for cervical cancer.",
keywords = "CIN1, CIN2+, HSIL, Immunocytochemistry, Ki-67, Liquid-based cytology, LSIL, MCM-2, p16, Pap smear, Proexc, Topo-2a",
author = "Terry Morgan and Michelle Berlin",
year = "2014",
month = "10",
day = "27",
doi = "10.1007/978-1-4939-2013-6_15",
language = "English (US)",
isbn = "9781493920136",
pages = "203--212",
booktitle = "Cervical Cancer: Methods and Protocols",
publisher = "Springer New York",

}

TY - CHAP

T1 - Immunocytochemical analysis of the cervical Pap smear

AU - Morgan, Terry

AU - Berlin, Michelle

PY - 2014/10/27

Y1 - 2014/10/27

N2 - Although immunostained cervical Pap smears are not yet FDA approved for clinical use, it is very likely that they will become widely employed in the near future to identify neoplastic squamous and iendocervical glandular cells when screening liquid-based cytological preparations (i.e., SurePath™ or ThinPrep™). The current problem with cytology complemented by high-risk human papillomavirus (HPV) testing is poor specificity. HPV testing provides superior sensitivity, but many women are infected with the virus, while very few have had persistent infections leading to carcinoma. Pathologists routinely use antibodies directed against the cyclin-dependent kinase inhibitor p16 (p16 INK4a) or a combination of antibodies directed against topoisomerase-2-alpha and minichromosome maintenance protein-2 (as in ProEx™ C) to improve diagnostic precision and accuracy in cervical tissue biopsies. This chapter will describe the immunocytochemical methods used by our group to immunostain cervical Pap smears and provide significantly improved positive predictive value when screening for cervical cancer.

AB - Although immunostained cervical Pap smears are not yet FDA approved for clinical use, it is very likely that they will become widely employed in the near future to identify neoplastic squamous and iendocervical glandular cells when screening liquid-based cytological preparations (i.e., SurePath™ or ThinPrep™). The current problem with cytology complemented by high-risk human papillomavirus (HPV) testing is poor specificity. HPV testing provides superior sensitivity, but many women are infected with the virus, while very few have had persistent infections leading to carcinoma. Pathologists routinely use antibodies directed against the cyclin-dependent kinase inhibitor p16 (p16 INK4a) or a combination of antibodies directed against topoisomerase-2-alpha and minichromosome maintenance protein-2 (as in ProEx™ C) to improve diagnostic precision and accuracy in cervical tissue biopsies. This chapter will describe the immunocytochemical methods used by our group to immunostain cervical Pap smears and provide significantly improved positive predictive value when screening for cervical cancer.

KW - CIN1

KW - CIN2+

KW - HSIL

KW - Immunocytochemistry

KW - Ki-67

KW - Liquid-based cytology

KW - LSIL

KW - MCM-2

KW - p16

KW - Pap smear

KW - Proexc

KW - Topo-2a

UR - http://www.scopus.com/inward/record.url?scp=84958664971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958664971&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-2013-6_15

DO - 10.1007/978-1-4939-2013-6_15

M3 - Chapter

C2 - 25348308

AN - SCOPUS:84958664971

SN - 9781493920136

SN - 9781493920129

SP - 203

EP - 212

BT - Cervical Cancer: Methods and Protocols

PB - Springer New York

ER -